Anti-tumor immunity in mismatch repair-deficient colorectal cancers requires type I IFN-driven CCL5 and CXCL10

J Exp Med. 2021 Sep 6;218(9):e20210108. doi: 10.1084/jem.20210108. Epub 2021 Jul 23.

Abstract

Colorectal cancers (CRCs) deficient in DNA mismatch repair (dMMR) contain abundant CD8+ tumor-infiltrating lymphocytes (TILs) responding to the abundant neoantigens from their unstable genomes. Priming of such tumor-targeted TILs first requires recruitment of CD8+ T cells into the tumors, implying that this is an essential prerequisite of successful dMMR anti-tumor immunity. We have discovered that selective recruitment and activation of systemic CD8+ T cells into dMMR CRCs strictly depend on overexpression of CCL5 and CXCL10 due to endogenous activation of cGAS/STING and type I IFN signaling by damaged DNA. TIL infiltration into orthotopic dMMR CRCs is neoantigen-independent and followed by induction of a resident memory-like phenotype key to the anti-tumor response. CCL5 and CXCL10 could be up-regulated by common chemotherapies in all CRCs, indicating that facilitating CD8+ T cell recruitment underlies their efficacy. Induction of CCL5 and CXCL10 thus represents a tractable therapeutic strategy to induce TIL recruitment into CRCs, where local priming can be maximized even in neoantigen-poor CRCs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / pathology
  • Chemokine CCL5 / immunology*
  • Chemokine CXCL10 / immunology*
  • Colonic Neoplasms / genetics
  • Colonic Neoplasms / immunology*
  • Colonic Neoplasms / pathology
  • Cytotoxicity Tests, Immunologic
  • DNA Mismatch Repair / immunology*
  • Female
  • Genomic Instability
  • Humans
  • Interferon Type I / immunology
  • Interferon Type I / metabolism*
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Lymphocytes, Tumor-Infiltrating / pathology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • MutL Protein Homolog 1 / genetics

Substances

  • Ccl5 protein, mouse
  • Chemokine CCL5
  • Chemokine CXCL10
  • Cxcl10 protein, mouse
  • Interferon Type I
  • Mlh1 protein, mouse
  • MutL Protein Homolog 1

Grants and funding